An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme

Trial Profile

An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Lucanthone (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Planned number of patients changed from 140 to 210 as reported by ClinicalTrials.gov.
    • 07 Aug 2012 New source identified and integrated (Clinical Trials Registry - India),
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top